Benitec Biopharma (NASDAQ:BNTC) Issues Earnings Results

Benitec Biopharma (NASDAQ:BNTC) released its earnings results on Friday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01, FiscalAI reports.

Benitec Biopharma Trading Down 0.6%

Shares of NASDAQ:BNTC traded down $0.05 on Friday, hitting $9.04. The company had a trading volume of 144,689 shares, compared to its average volume of 148,826. The stock has a market cap of $315.41 million, a price-to-earnings ratio of -9.22 and a beta of 0.26. The stock has a 50 day moving average price of $9.74 and a 200 day moving average price of $11.41. Benitec Biopharma has a 1-year low of $7.89 and a 1-year high of $14.39.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wall Street Zen lowered Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. HC Wainwright reissued a “buy” rating on shares of Benitec Biopharma in a research report on Monday, November 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Thursday, October 15th. Wedbush increased their target price on shares of Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, October 6th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.00.

Benitec Biopharma Company Profile

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.